Updated time: 2024-10-24 15:40:28
Developing new therapeutic strategies to overcome drug resistance of cancer cells is an ongoing endeavor. We identified ethyl 4-oxo-2-phenyl-1,4-dihydroquinoline-6-carboxylate derivatives as low-toxicity inhibitors of lung and breast cancer cell proliferation and xenograft tumor growth. These compounds are active against other cancer cell lines and are able to bind in the colchicine-binding pocket of β-tubulin, thereby inhibiting microtubule assembly and, consequently, inducing mitotic arrest and apoptosis. Notably, these compounds overcame P-glycoprotein efflux pump (P-gp) and β-tubulin alterations that lead to acquired resistance against microtubule-targeting drugs of cancer cells and are lead compounds that overcome acquired resistance to microtubule-targeting agents of cancer cells.
- Anti-triple negative breast cancer including the paclitaxel-resistant type
- Overcome p-glycoprotein mediated multidrug-resistance and β-tubulin alterations that lead to acquired resistance against microtubule-targeting drugs of cancer cells
- Anti-EGFR TKI resistant lung cancer

Fig1. These compounds are active against broad cancer cell lines with low-toxicity to normal cells.
03A-1080306
2020-02-03
TW I757726、CN ZL 2020 1 0309494.7、 US 11,638,705 B2 、US 12,109,207 B2
- Breast cancer drug
- Lung cancer drug
- Other cancer drug
Rong-Jie Chein
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Fig2. These compounds can overcome p-glycoprotein mediated multidrug-resistance.

ETHYL 4-OXO-2-PHENYL-1,4-DIHYDROQUINOLINE-6- CARBOXLATE DERIVATIVES AND USES THEREOF FOR TREATING PROLIFERATIVE DISEASES AND INFECTIOUS DISEASES